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Abstract
Background: Patients often report neurocognitive difficulties after neuroborreliosis (NB). The frequency and extent
of cognitive problems in European patients have been studied incompletely.
Methods: Sixty patients received a neurological and neuropsychological work-up 6 months or longer after treatment
for proven NB. Quality of life, psychiatric symptom load, and brain atrophy were measured. All results were compared
with a group of 30 healthy control persons adapted for age, gender and education being serologically negative for
Borrelia burgdorferi senso latu. A cognitive sum score and a global sum score including cognitive, psychological results
and quality of life data was calculated for both groups.
Results: Patients after NB showed a lower (i.e. more impaired) score on the Scripps Neurological rating scale (SNRS),
but the observed neurological deficits were generally mild (mean ± SD: 97.1 ± 4.7 vs. 99.1 ± 2.4, p = 0.02). The mean
neuropsychological domain results of the NB group were all within the normal range. However, a lower performance
was found for the frontal executive function z-values (mean ± SD –0.29 ± 0.60 vs. 0.09 ± 0.60; p = 0.0059) of NB
patients. Comparing the global sum score (mean ± SD 11.3 ± 4.2NB vs. 14.3 ± 2.9control , p = 0.001) and the cognitive
sum score of the NB group with those of the control group (mean ± SD -0.15 ± 0.42NB vs. 0.08 ± 0.31control , p =
0.0079), both differences were statistically different. The frequencies of impaired global sum scores and those of the
pathological cognitive sum scores (p = 0.07) did not differ statistically. No significant differences were found for
health-related quality of life (hrQoL), sleep, psychiatric symptom load, or brain atrophy.
Conclusion: The mean cognitive functions of patients after proven NB were in the normal range. However, we were
able to demonstrate a lower performance for the domain of frontal executive functions, for the mean cognitive sum
score and the global sum score as a sign of subtle but measurable sequelae of neuroborreliosis. Brain atrophy is not a
common consequence of neuroborreliosis.
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Background
There are only few studies on cognitive symptoms in
patients who have had the European form of neurobor-
reliosis (NB). This gap in our knowledge gives rise to
speculations about the clinical course of NB, often lead-
ing to the impression that NB inevitably results in severe
neurocognitive sequelae. Population-based studies clari-
fied the low probability of developing either a chronic
form of NB [1]. In a study with 20 patients with previ-
ously diagnosed NB, Benke et al. [2] found significantly
poorer verbal learning and memory functions paired with
problems concerning the executive functions as residual
symptoms after NB. The second, more recent study from
Scandinavia applying a short test battery of four neuropsy-
chological tests demonstrated significantly lower mean
results in the NB group while the extent of the impairment
was rather mild [3]. In a similar study from the U.S. with
44 patients, however, 36 % showed impaired scores when
tested with a naming test compared to 14 % of healthy
control persons [4]. Whether the difference between the
studies is due to the divergent forms of neuroborreliosis in
Europe and America, or whether it only represents differ-
ences in methodology remains to be clarified. In addition,
our study aims to elucidate the extent and frequency of
brain atrophy caused by NB as reported by Tarasow et al.
in 60 % of their patients [5].
Methods
Patients
We reviewed the clinical files of patients from two neu-
rological centres (University Medical Centre Göttingen
and Asklepios Klinik Schildautal/Seesen, both Germany)
who had been diagnosed and treated for NB from 1994
to 2009. Patients had to be between 15 and 70 years of
age at the time of treatment. Patients with other neuro-
logical or psychiatric diseases (including alcohol or any
substance abuse) were excluded. Eligible NB patients had
to show a documented typical clinical presentation of NB
in combination with positive serum antibodies against
Borrelia burgdorferi sensu lato and either a cerebrospinal
fluid (CSF) pleocytosis with an elevated Borrelia-specific
CSF-to-serum antibody index (AI) or a CSF pleocytosis
accompanied by an erythema migrans (EM) at the time of
presentation. All eligible former patients were invited by
mail. The treatment had to be completed for at least six
month to participate in this study. Sixty patients partic-
ipated. According to our power calculations which were
based on a paper published by McAuliffe and colleagues
[6], a sample size of 10 per group would have been suffi-
cient to reach a statistical power of 80 % for the cognitive
sum score.With the sample size of 60, the statistical power
of the presented calculations is estimated > 90 %. All
patients had completed their antibiotic treatment regimen
according to the German guidelines for neuroborreliosis.
Most of them were treated with ceftriaxone (n = 51),
seven with penicillin G, and two with doxycycline. The
exclusion tree is given in Fig. 1. The control group con-
sisted of 30 neurologically healthy, serologically Borrelia-
negative volunteers. This group was adapted for gender
(f/m = 20/40NB vs. 12/18Control, p = 0.64), age (mean± SD
46.9 ± 13.9NB vs. 42.3 ± 16.0Control years, p = 0.19), and
years of education (10.6± 1.7NB vs. 11.2± 1.8Control years,
p = 0.14). Likewise, marital status and occupational situ-
ation in the control group and the patient group did not
differ (Table 1). The control population was recruited by
putting bulletins at several public pin boards. As a com-
pensation for their efforts, all participants (also those from
the NB group) received a refund of travel expenses.
The study was approved by the Ethics Committee of the
University Medical Centre Göttingen, and all participants
gave their written informed consent.
Fig. 1 Study exclusion tree
Schmidt et al. BMC Neurology  (2015) 15:139 Page 3 of 11
Table 1 Comparison of baseline parameters between the two study groups
Parameter Control group (n = 30) NB group (n = 60) p (univariate) p (multivariate)
Age [years] 42.3 ± 16.0 46.9 ± 13.9 0.1862 -
42.5 (19.0–72.0) 46.0 (18.0–71.0)
Gender 0.6413 -
Female 11 (40 %) 20 (33.3 %)
Male 18 (60 %) 40 (66.7 %)
Family status 0.5106 -
unmarried 4 (13.3 %) 10 (16.7 %)
married 16 (53.4 %) 39 (65.0 %)
allied 8 (26.7 %) 9 (15.0 %)
divorced 1 (3.3 %) 1 (1.7 %)
widowed 1 (3.3 %) 1 (1.7 %)
Education [years] 11.2 ± 1.8 10.6 ± 1.7 0.1428 -
12.0 (8.0–13.0) 10.0 (8.0–13.0)
Full-time work 0.8233 -
no 16 (53.3 %) 29 (48.3 %)
yes 14 (46.7 %) 31 (51.7 %)
Part-time work 1.0
no 25 (83.3 %) 50 (83.3 %)
yes 5 (16.7 %) 10 (16.7 %)
Unemployed 0.5506 -
no 30 (100.0 %) 58 (96.7 %)
yes 2 (3.3 %) 2 (3.3 %)
Retired 1.0 -
no 26 (86.7 %) 53 (88.3 %)
yes 4 (13.3 %) 7 (11.7 %)
Descriptive values are means ± standard deviations and medians (minima-maxima)
Examination
Both groups received a thorough standardized neuro-
logical examination quantified with the Scripps neu-
rological rating scale (SNRS) [7], a neuropsychological
evaluation including measurements for attention (Test-
batterie zur Aufmerksamkeitsprüfung, TAP) [8] (subtests
selective attention (alertness); stimulus selectivity (go-
no-go) and divided attention)). Short-term and work-
ing memory were assessed with the German version of
the Wechsler Memory Scale-R (WMS-R) (subtests digit
span forward/backward (fw/bw); block span fw/bw; logi-
cal memory (LM), part I) [9], the first trial of the California
Verbal Learning Test (CVLT) [10] and the two-back task
from the TAP battery [8]. Verbal learning and long-term
memory were tested with WMS-R (subtests verbal paired
associates; LM, part II) [9], CVLT [10] and with the Verbal
Learning Test (VLT) [11].
Non-verbal learning and memory were measured with
the WMS-R (subtest visual paired associates) [12], the
Rey-Osterrieth complex figures task (ROCF) [13], the
Non-Verbal Learning Test (NVLT) [14], Lern- und
Gedächtnistest 3 (LGT-3) (subtest city map) [15]. Exec-
utive functions/psychomotor speed were examined by
verbal fluency tasks Regensburger Wortflässigkeitstest
(RWT) [16] (subtests lexical fluency with and without
alterations, subtests semantic fluency with and without
alterations), figural fluency task (FF) [17], a verbal con-
cept formation task from Hamburg-Wechsler Intelligen-
ztest für Erwachsene-R (HAWIE-R); subtest similarities
(Gemeinsamkeiten finden) [12], CVLT clustering and a
figural concept formation task, Wisconsin Card Sorting
Test (WCST) [18], and the tower of Hanoi test [19]. Visuo-
constructive functions were examined with the HAWIE-R
(subtest Mosaic test [12]) and the ROCF score for figure
copying [13]. Z-values were calculated for both groups
according to the respective test manuals before group
comparisons. Domain scores for each subject were calcu-
lated based on the mean test results of all tests from the
respective domain. Tests were defined as pathologically
impaired if the z-value was < -1.5. A domain was judged
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as pathological if more than half of the included tests of
the respective domain showed z-values below -1.5.
Psychiatric symptoms
Scores for depressive mood, anxiety, fatigue, fibromyal-
gia symptoms and the global psychiatric symptom load
were measured with the German versions of the following
tools: Beck’s Depression Inventory (BDI) [20], Hamilton
Depression Scale (HAMD) [21], and Symptom Checklist
90R (SCL-90R) [22], the Hospital Anxiety and Depres-
sion Scale (HADS-D) [23], State-Trait-Anxiety Inventory
(STAI X-1 and X-2) [24], the Fibromyalgia Impact Ques-
tionnaire (FIQ) [25], and the Functional Assessment of
Chronic Illness Therapy-Fatigue (FACIT-Fatigue) [26].
Health-related quality of life (hrQoL)
Self-assessment questionnaires focused on the partici-
pant’s global satisfaction (Satisfaction of Life Scale [27],
SF-36 [28]), and sleep quality (Pittsburgh Sleep Quality
index (PSQI) [29].
All self-assessment questionnaires were sent to the par-
ticipant after the first telephone contact, i.e. before clinical
presentation, to allow him/her to fill in the answers in a
familiar environment.
Brain atrophy
Fifty-four out of sixty former patients and all of the con-
trol persons agreed to be examined by MR tomography. A
standardized protocol for magnetic resonance (MR) imag-
ing of the brain was used to determine the individual brain
atrophy in relation to the skull volume. The normalized
volumes of the whole brain, grey matter, white matter,
peripheral grey matter, and the inner CSF volume were
measured with the voxel-based method FSL-Sienax. High
resolution T1-weighted MR scans of the brain (3D turbo
fast low angle shot (FLASH), 1 mm3 isotropic resolution,
repetition time: 2250 ms, inversion time: 900 ms, echo
time: 3.26 ms, flip angle: 9deg, 3 Tesla (Magnetom TIM
Tio, Siemens Healthcare, Erlangen, Germany) served as
the data source. In short, the Sienax technique references
the above-mentioned segmented tissue volumes to the
size of the skull. Size-corrected segmented volumes are in
turn compared to the respective volumes derived from a
normalized standard brain. Thus an estimation of brain
atrophy can be obtained with one punctual measurement
[30].
Statistical methods
Categorial parameters were compared between the two
groups by Fisher’s exact test and metric parameters
(e.g. domain means) by either the t-test or the Mann-
Whitney U-Test. The t-test was employed when data were
normally distributed, which was checked by quantile-
quantile plots. In order to further evaluate the clinical
relevance of these differences, we compared patients and
healthy controls with respect to the existence of patho-
logical cognitive domains (i.e., domains with more than
half of the tests showing pathological results, defined as
z-values < -1.5).
In order to enable a comparison with other European
results, we also used an algorithm proposed by Eikeland
et al. [3] to build a sum score incorporating 19 of the
subtasks (Table 2): The individual sum scores were fur-
ther categorized with respect to the mean sum score of
the control group. In detail, three categories were formed:
normal (≤ 1 SD below the mean sum score of the control
group), deficit (> 1, ≤ 2 SD below the mean sum score
of the control group) and impaired (> 2 SD below the
mean sum score of the control group). The distribution of
the three categories was compared between NB and con-
trol group by Fisher’s exact test. Those parameters which
were significantly different in the univariate analysis were
combined in a multivariate logistic regression analysis to
assess the independence of the difference. Frequencies
were compared with a two-tailed Fisher’s exact test. All
tests were carried out using the free software R (version
2.8, http://www.r-project.org) with a significance level of




The diagnosis and treatment of the former NB patients
dated back 4.5 ± 3.7 years (mean ± SD). When they pre-
sented with neuroborreliosis, patients were 42.9 ± 14.4
years old; 39 % complained of headaches, 10 % expe-
rienced fever, in 20 % signs of meningitis were present
(mostly end-grade nuchal rigidity), 44 % showed a facial
palsy, in 66 % radicular symptoms were predominant,
7 % reported cognitive alterations, and in 7 % an altered
mood was observed. Only 45 % remembered a tick bite
before the first symptoms of NB began. Forty percent
had noticed local erythema. 12.5 % developed the neu-
rological symptoms that led to hospital admission within
several days. The majority of NB patients experienced a
subacute course, 53.6 % developing the symptoms grad-
ually within 14 days. In 28.6 % symptom development
took up to two month until diagnosis, and a minority
of patients (5.3 %) had neurological symptoms for more
than two months before the diagnosis was made. One
patient with radicular pain, who waited more than one
year before the correct diagnosis was made, suffered at the
time of presentation from a chronic myelitic NB and kept
residual symptoms, especially urine incontinence. On re-
examination, 56 % of the NB group displayed (mostly
subtle) neurological signs resulting in a significantly lower
SNRS when compared to the healthy control group (97.1
± 4.8 vs. 99.3 ± 2.2, p = 0.02). Of the patients with
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Table 2 Comparison of cognitive and neuropsychiatric data between the two study groups
Parameter Control group (n = 30) NB group (n = 60) p (univariate) p (multivariate)
State-trait Anxiety Inventory 31.7 ± 4.5 33.7 ± 6.3 0.0761 -
(STAI) State (X1) 31.0 (22.0–44.0) 33.4 (21.0–53.0)
State-trait Anxiety Inventory (STAI) Trait (X2) 31.2 ± 6.8 35.3 ± 10.6 0.0345 n.s.
30.0 (21.0–49.9) 32.0 (20.0–67.0)
Hamilton Depression Scale 4.6 ± 5.9 8.6 ± 8.0 0.010 n.s.
3.0 (0.0–20.0) 6.0 (0.0–28.0)
HADS A 3.1 ± 2.8 3.1 ± 2.8 0.0190 n.s.
3.0 (0.0–11.0) 4.0 (0.0–15.0)
HADS D 2.4 ± 3.3 3.9 ± 3.8 0.0737 -
1.0 (0.0–12.0) 3.0 (0.0–15.0)
Sleep quality (PSQI) 4.8 ± 3.6 4.5 ± 3.0 0.7454 -
4.5 (0.0–14.0) 4.0 (0.0–15.0)
Diener’s Quality of Life Score 20.4 ± 3.5 19.2 ± 4.3 0.1919 -
20.0 (9.0–25.0) 20.0 (8.0–25.0)
Quality of Life Bar 7.4 ± 2.2 6.4 ± 2.2 0.0615 -
8.1 (1.9–10.0) 7.0 (1.1–9.7)
NottinghamActivities of Daily Living (NADL) 87.8 ± 1.3 86.8 ± 2.1 0.0135 n.s.
88.0 (81.0–88.0) 88.0 (81.0–88.0)
Beck’s Depression Index (BDI) 3.1 ± 3.6 4.9 ± 6.5 0.1087 -
2.0 (0.0–15.0) 2.0 (0.0–15.0)
Fibromyalgia Impact Questionnaire (FIQ) 6.2 ± 7.2 17.9 ± 19.8 0.0001 n.s.
3.2 (0.0–35.0) 10.4 (0.0–78.6)
Working memory −0.09 ± 0.55 −0.27 ± 0.56 0.1525 -
−0.01 (−1.54–0.85) −0.26 (−1.38–1.08)
Verbal memory −0.11 ± 0.58 −0.37 ± 0.67 0.0603 -
−0.07 (−1.47–0.83) −0.27 (−1.83–0.88)
Non-verbal memory 0.08 ± 0.61 −0.13 ± 0.50 0.1037 -
0.23 (−1.61–1.34) −0.10 (−1.36–0.84)
Visuo-constructive functions 0.62 ± 0.59 0.42 ± 0.78 0.1771 -
0.62 (−0.44 –1.72) 0.57 (−1.77–1.81)
Frontal executive functions 0.09 ± 0.60 −0.29 ± 0.60 0.0059 0.0161
0.21 (−1.43–1.19) −0.22 (−1.62–1.04)
Alertness −0.17 ± 0.39 −0.23 ± 0.45 0.5427 -
−0.16 (−1.16–0.68) −0.21 (−1.23–0.75) -
Cognitive sum score 0.08 ± 0.31 −0.15 ± 0.42 0.0079 0.01
0.1 (−0.66–0.78) −0.12 (−1.03–0.93)
SCL 90r GSI 41.3 ± 11.8 46.6 ± 14.9 0.0772 -
42.0 (21.0–74.0) 45.0 (23.0–75.0)
SCL 90r PST 40.9 ± 11.3 45.8 ± 14.3 0.0852 -
41.0 (21.0–74.0) 44.0 (23.0–79.0)
Global sum score 0.7 ± 0.30 −0.15 ± 0.42 0.0083 -
0.10 (−0.66–0.78) −0.12 (−1.03–0.93)
Descriptive values: means ± standard deviations and medians (minima-maxima)
Bold face: Significant differences
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residual neurological signs, 79 % (44 % of all patients)
were in the range of “mild impairment” (SNRS score range
93 to 99), 15 % (8 %) could be grouped into “moder-
ate impairment” (SNRS score range 92 to 86), and only
two patients (6 % of those with neurological symptoms;
3 % of all patients) remained severely impaired (SNRS
≤ 85) according to the SNRS grading used by the IFNB
MS study group [31]. In all patients, the symptoms could
at least be explained as residua of the initial symptoms
of NB. However, due to the retrospective design of the
study with it’s long interval between disease and follow-up
examination, other contributing factors eventually for-
gotten or not mentioned by the participants cannot be
excluded.
Themost frequent abnormalities found in the neurolog-
ical examination were sensory symptoms, especially radic-
ular pain or hypaesthesia and residual facial asymmetry.
In detail, of the 33 patients with neurological symptoms
at reexamination, 45 % (25 % NB; 7 % Control) had mild
facial palsy, 48 % (27 % NB; 11 % Control) showed sensory
deficits, judged to be mild in all but one patient who was
rated as being moderately impaired. Motor impairment
was found in 21 % of patients with neurological symptoms
(12 % NB, 0 % Control), again judged to be mild in all but
one patient. Mild reflex differences were present in 30 % of
the patients with residual neurological signs of NB (17 %
NB; 11 % Control). A positive Babinski sign was found in
one NB patient. Mild cerebellar signs were recorded for
12 % in the patients with neurological symptoms (7 % NB;
0 % Control). Gait and balance were found to be impaired
in 27 % of NB patients with neurological symptoms (15 %
NB, 4 % Control); the impairment was judged to be mild
in 7, moderate in 2 patients. 3 patients reported problems
with bladder/bowel functioning (5 % NB; 0 % Control).
Mood alterations were recorded in 4 patients (7 % NB;
0 % Control). Cranial nerve signs were present in 12 %
of patients with neurological impairment (7 % NB; 4 %
Control).
The scores of the SNRS at re-examination were nega-
tively correlated with the patients’ age at admission and
with the interval from the onset of symptoms of NB until
the start of antibiotic therapy, i.e. the older patients and
the longer the delay in treatment, the poorer the neuro-
logical outcome score (Spearman’s r = –0.34, p = 0.01, and
r = –0.32, p = 0.02).
Neuropsychological evaluation
The detailed results test by test are given in Table 2.
In all domains the patient group’s mean z-values were
lower than in the control group (Fig. 2). However, all
group means fell within the normal range, and a sta-
tistically significant difference was only present in the
domain of frontal executive functions (–0.29 ± 0.60NB
vs. 0.09 ± 0.60Control, p = 0.006). The independence of
this observation could be confirmed by logistic regression
analysis (p = 0.016). In addition, the difference between
both cognitive sum scores showed a statistical difference
(11.3 ± 4.2NB vs. 14.3 ± 2.9Control, p = 0.001). Based on
a cut-off value of z < -1.5 for the domains’ means, we did
not find any resulting pathological mean (working mem-
ory, non-verbal learning/memory, or alertness) for either
group (Table 3).
For the frequencies of pathological domains, none of
the differences between patient and control group differed
significantly (verbal learning and memory: n = 6/60NB vs.
n = 0/30Control, p = 0.173; visuo-constructive functions
n = 5/60NB vs. n = 0/30Control, p = 0.165; frontal execu-
tive functions n = 1/60NB vs. 0/30Control, p = 1.00). Using
the method of Eikeland et al., 15 sum scores of the NB
patients but only two sum scores of persons belonging to
the Control group were classified as impaired (Table 4)
when comparing the frequencies of all three catergories
(“normal”, “impaired”, “defect”) of the two groups with
each other by means of the Chi2-test (p = 0.07). How-
ever, comparing the frequencies of impaired test results
according to Eikeland et al. in the NB group with those in
the control group, Fisher’s exact test showed a significant
difference, i.e. a more frequent occurence of a deficit in
the NB group (p = 0.0435) (see also Fig. 3). There were
no correlations between the scores for anxiety, depressive
mood, sleep quality, general quality of life or psychiatric
symptom load with the z-values of the neuropsychological
domains.
Questionnaires for psychiatric symptom load, hrQoL,
activities of daily living
For all questionnaires except the PSQI questionnaire,
patients after NB showed z-values with a trend towards
more impairment than the control group. However, most
of the NB patients recovered well and the mean results
did not exceed the normal range. The differences between
the NB group and the control group were significant
for the anxiety subscale of the Hospital Anxiety Scale-A
(HADS-A), the STAI-X2 scale, and the Hamilton Depres-
sion Scale. Patients after NB also displayed significantly
higher scores in the Fibromyalgia Impact Questionnaire
than the healthy control group.
The NADL score was lower (i.e. “more impaired”) in
patients after NB in the univariate analysis. Although we
found these group differences, all mean values fell within
the normal range and were far from being pathologi-
cal. Using the multivariate analysis, none of the above
mentioned univariate differences yielded significant dif-
ferences (see Table 2). The BDI correlated significantly
(r = 0.3; p = 0.03) with the time interval from onset of
symptoms to treatment. In contrast, we could not detect
any significant correlations between the scores for depres-
sion and the cognitive domains.
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Fig. 2 Cognitive domain results. NB: Neuroborreliosis groups; C: control group; asterisk: significant differences
Measures of brain atrophy
Neither the normalized brain volumes, nor the inner CSF
spaces, nor the white or grey matter volumes differed
between the groups (Table 5).
Discussion
The cognitive residuals of proven NB in Europe have
been examined in only two studies [2, 3], reporting con-
siderable cognitive long-term sequelae. A study from the
U.S. found poorer cognitive functioning after NB as well,
but the differences did not reach statistical significance
[32]. In the present study we demonstrate, with a suffi-
cient number of patients, that after proven NB the mean
performance in frontal executive functions is significantly
poorer than in the control group, and that impaired cogni-
tive sum scores are observed significantly more frequently
in the NB than in Control group subjects. In addition,
patients after NB were significantly more anxious, com-
plained more often of muscle pain and had lower scores
(i.e. were more impaired) in their standardized neurologi-
cal examination. All these differences, however, were only
group differences. The mean results for the NB group
were all in the normal range, far from being pathological.
The comparison of the frequencies of impaired cognitive
sum scores according to Eikeland et al. did not yield a
statistical difference [3]. Looking at the frequencies of
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Table 3 Frequency of pathological performances per domain
and group
Parameter Control NB p (Fisher two-tailed
group⊕ group exact test)
Working memory 0/30 0/60 -
Verbal memory 0/30 6/60 0.173
Non-verbal memory 0/30 1/60 1.0
Visuo-constructive functions 0/30 0/60 -
Frontal executive functions 2/30 1/60 0.257
Cognitive sum score 0/30 0/60 1.0
⊕Subjects with more than 50 % pathological (z ≤ -1.5) scores per domain
z-values < –1.5 per domain in individual persons, there
were no statistical differences between the control and
patient group. This is in line with several studies focusing
on the global clinical and neurological outcome after NB
[33–36].
Taken together, the patients in our study - after ade-
quately treated NB - had a distinctively more favourable
outcome than those of the older comparable study [2] and
a slightly better outcome when compared to the newer
study from Scandinavia [3]. In both of the mentioned
studies significant and much more important problems
were observed in the domains of verbal learning/memory,
attention and executive functions after NB. The reason for
this discrepancy might be the smaller group size that was
examined in both trials resulting in a possible selection
bias. Another reason for the significantly poorer outcome
of the patients of Benke et al., however, might also be the
interval of 15 years between the studies. Today’s aware-
ness on the part of medical doctors and patients with
regard to signs of NB might have grown, possibly leading
to earlier presentation, earlier diagnosis and thus earlier
and more effective treatment than in the past. This might
also be reflected by the fact that most of our patients
sought medical treatment within 14 days after the onset of
symptoms. Although cognitive results in our patients were
not negatively correlated with the delay of treatment, this
might not be transferable to geographic areas where peo-
ple tend to wait longer with their presentation. The more
recent previous study, however, was performed with a suf-
ficient number of patients but compared the raw scores of
Table 4 Frequencies of categorized global sum scores per group
Sum score NB group Control group p(Chi2-Text
categories (N = 60) (N = 30)
Normal 41 (68 %) 27 (90 %) 0.07
Deficit 4 (7 %) 1 (7 %)
Impairment 15 (25 %) 2 (3 %)
Categories: Normal: z ≥-1, Deficit: z = <-1 and = z ≥-2, Impaired < z = -2
the tests instead of age, gender and education-corrected
z-values of their data.
Our interpretation of the present data is that function-
ally relevant cognitive deficits after proven NB are rare
exceptions and not the rule. However, also in our analysis,
there were more participants from the NB group below a
cognitive sum score of z < –2 than in the healthy control
group (8 of 60 vs. 2 of 30). This difference did not, how-
ever, reach statistical significance in contrast to the study
from Scandinavia [3].
The results of the cognitive examinations in our
NB group compare well with the questionnaires that
addressed psychological symptoms, quality of life, and
activities of daily living; again, with the exception of
sleep quality, we observed a higher symptom load in NB
patients, but the mean values for the symptom load were
all in the normal range. Similar results were found in
the Scandinavian population examined by Eikeland and
co-workers (even though they interpreted their findings
differently with respect to clinical relevance) [37]. As in
the study of Krupp et al. [38], who examined patients after
the North American form of NB, the cognitive functions
in our European study population did not correlate with
the scores of the depression questionnaires.
These findings are in contrast to the often severe cog-
nitive and psychiatric complaints of patients referred to
neurological departments because of suspected NB, who
display positive serologic tests but not the typical signs
for NB in the CSF [39]. Despite the described difference
for the frontal executive functions in NB patients com-
pared to control persons that finally led to the significantly
lower cognitive sum score, the neuropsychological results
were congruent with the favourable neurological outcome
found previously in several other studies on NB patients,
e.g. [1–3, 35]. Our interpretation of these findings is that
in the vast majority of patients, neuroborreliosis does has
not have a relevant impact on their cognitive functions.
According to our data, brain atrophy as it occurs in
patients after purulent meningitis [40] does not represent
a common feature of neuroborreliosis. The mean brain
volume and the volume of the separate brain tissues (mea-
sured automatically - thus examiner-independent) were
almost identical in both groups. The high proportion of
brain atrophy in patients after NB reported by Tarasow
et al. [5] may be explained either by the small number of
patients (n = 14) in that study, a selection bias (the data
were collected in a department of radiology which prob-
ably did not regularly receive asymptomatic patients after
NB), or the fact that the patients may have been diagnosed
and treated with a considerable delay after infection.
This does not mean, however, that our data rule out
the possible individual occurrence of severe long-term
sequelae after NB. If cognitive impairments occur, the
domain of frontal executive functions (e.g. psychomotor
Schmidt et al. BMC Neurology  (2015) 15:139 Page 9 of 11
Fig. 3 Distribution of congnitive sum scores. NB: Neuroborreliosis groups; C: control group
speed, gathering and structuring of information, chang-
ing behaviour in response to changing surroundings) is
the most probable to be affected after neuroborreliosis.
The degree of these impairments, however, is that small
that alterations in neurocognitive functioning will often
be only discernible by extensive neuropsychological test-
ing or just by the affected person him- or herself. As a
consequence, assuming that our control group was rep-
resentative for the study group (and we do not find any
reasons against this), it can be concluded that NB may
leave subtle but discernable traces for individual patients,
especially concerning the frontal executive functions that
only exceptionally are severe enough to affect the activities
of daily living. Of course, our retrospective design bears
the danger of a bias; in spite of the control group it cannot
be ruled out that the pre-morbid cognitive functioning –
especially the executive functions- of the NB group might
have been lower than that of the control group. To fal-
sify or confirm this hypothesis, however, would require a
large population-based prospective trial with a neuropsy-
chological evaluation of persons before and after proven
NB.
Table 5 Comparison of the volumetric cerebral MR analysis of the two study groups
Parameter Control group (n = 30) NB group (n = 54) p
Peripheral grey matter [ml] 621.4 ± 50.4 618.5 ± 47.2 0.8118
624.4 (514.7–719.7) 619.7 (518.7–764.4)
Ventricular volume [ml] 42.0 ± 15.7 42.4 ± 19.3 0.9516
40.1 (19.9–8.5) 38.9 (17.5–13.6)
Total grey matter [ml] 818.0 ± 65.1 811.6 ± 60.6 0.6642
817.3 (672.1–943.2) 812.2 (690.5–991.1)
Total white matter [ml] 691.0 ± 42.6 691.5 ± 36.7 0.9145
687.9 (566.9–763.5) 690.5 (623.2–781.5)
Total brain volume [ml] 1509.0 ± 89.8 1503.1 ± 79.3 0.8409
1511.0 (1298.0–1681.0) 1513.0 (1324.0–1679.0)
Descriptive values are means ± standard deviations and medians (minima-maxima)
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Finally, it should be noted that small differences in
favour of the control group might vanish with a control
group consisting of former patients who had undergone
hospital treatment for other non-neurological diseases,
because such an event might leave its traces on a sub-
ject’s general well-being. This issue might be discussed as
a possible shortcoming of the study.
Conclusions
We found a measurable poorer cognitive functioning in
the domain of frontal executive functions and for the
cognitive sum score after NB while all other domains
remained unaffected. The differences that we found were
subtle. The patients’ brain volumes remained unaffected
by NB.
This paper has been written according to the STROBE
criteria.
Abbreviations
NB: Neuroborrelliosis; SNRS: Scripps neurological rating scale; SD: Standard
deviation; CSF: cerebrospinal fluid; AI: Antibody index; EM: Erythema migrans;
f/m: Female/male; TAP: Testbatterie zur Aufmerksamkeitsprüfung; test battery
for alertness; WMS-R: Wechsler memory scale-r; fw/bw: Forward/backward;
LM: Logical memory; CVLT: California verbal learning test; VLT: Verbal learning
test; ROCF: Rey-osterrieth complex figure task; LGT-3: Lern- und Gedächtnistest
3; learning and memory test 3; RWT: Regensburger wortflüssigkeitstest; FF:
Figural fluency task; HAWIE-R: Hamburg-wechsler intelligenztest für
Erwachsene-R; Hamburg-Wechsler intelligence test for adults-R; WCST:
Wisconsin card sorting test; BDI: Beck’s depression inventory; HAMD: Hamilton
depression scale; SCL-90R: Symptom checklist 90R; STAI X1/2:
State-trait-anxiety inventory; FIQ: Fibromyalgia assessment questionnaire;
FACIT: Functional assessment of chronic illness therapy-fatigue; hrQoL:
Health-related quality of life; SF-36: Satisfaction of life scale; PSQI: Pittsburgh
sleep quality index; MR: Magnetic resonance; FLASH: Fast low angle shot.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Carsten Schmidt-Samoa performed the neuropsychological assessment and
was involved in the assembly of the test battery. Marija Djukic, Roland Nau and
Manfred Holzgraefe contributed to the recruitment and neurological
examination of patients and the control persons. Peter Dechent was
responsible for the MRI-examinations. Nicole von Steinbüchel was involved in
the measurement of quality of life parameters. Joachim Blocher and Helmut
Eiffert contributed in the measurement of microbiological and neurochemical
parameters. Klaus Jung supervised and guided the statistical evaluation of
data. Holger Schmidt was the principal investigator, designed the study,
supervised the data collection and wrote the paper. All co-authors have read,
revised and approved the paper.
Acknowledgements
We thank Mrs. C. Crozier for the thorough proof-reading as a native speaker.
This work was supported by grants from the Niedersächsisches Ministerium
für Wissenschaft und Kultur (Grant-No. 11.4-76221-12-1/06, Ministry of Science
and Culture of Lower Saxony, Hannover, Germany). R.N. is supported in
addition by a grant from the Else-Kröner-Fresenius Foundation. Neither the
Ministry nor the Else-Kröner-Fresenius Foundation, as the funding sources, had
any involvement in the study design, the collection and analysis of data, the
interpretation of the results or in the writing of the review, nor was the decision
to submit the paper to BMC NEUROLOGY influenced by the funding sources.
Received: 10 February 2014 Accepted: 17 July 2015
References
1. Hansen K, Lebech AM. The clinical and epidemiological profile of lyme
neuroborreliosis in denmark 1985-1990. a prospective study of 187
patients with borrelia burgdorferi specific intrathecal antibody
production. Brain. 1992;115(Pt 2):399–423. 0006-8950 (Print) 0006-8950
(Linking) Case Reports Journal Article Research Support, Non-U.S. Gov’t.
2. Benke T, Gasse T, Hittmair-Delazer M, Schmutzhard E. Lyme
encephalopathy: long-term neuropsychological deficits years after acute
neuroborreliosis. Acta Neurol Scand. 1995;91(5):353–7. 0001-6314 (Print)
0001-6314 (Linking) Journal Article.
3. Eikeland R, Ljostad U, Mygland A, Herlofson K, Lohaugen GC. European
neuroborreliosis: neuropsychological findings 30 months post-treatment.
Eur J Neurol. 2012;19(3):480–7. Eikeland, R Ljostad, U Mygland, A
Herlofson, K Lohaugen, G C England Eur J Neurol. 2012 Mar;19(3):480-7.
doi: 10.1111/j.1468-1331.2011.03563.x. Epub 2011 Oct 15.
4. Svetina C, Barr W, Rastogi R, Hilton E. The neuropsychological
examination of naming in lyme borreliosis. Appl Neuropsychol;6:33–8.
5. Tarasow E, Ustymowicz A, Zajkowska J, Hermanowska-Szpakowicz T.
[neuroborreliosis: Ct and mri findings in 14 cases. preliminary
communication]. Neurol Neurochir Pol. 2001;35(5):803–13. 0028-3843
(Print) 0028-3843 (Linking) Case Reports English Abstract Journal Article.
6. McAuliffe P, Brassard MR, Fallon B. Memory and executive functions in
adolescents with posttreatment lyme disease. Appl Neuropsychol.
2008;15(3):208–19. 1532-4826 (Electronic) 0908-4282 (Linking) Journal
Article.
7. Sipe JC, Knobler RL, Braheny SL, Rice GP, Panitch HS, Oldstone MB. A
neurologic rating scale (nrs) for use in multiple sclerosis. Neurology.
1984;34(10):1368–72. 0028-3878 (Print) 0028-3878 (Linking) Journal Article
Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.S.
8. Becker M, Sturm W, Willmes K, Zimmermann P. Normierungsstudie zur
aufmerksamkeitstestbatterie (tap) von zimmermann und fimm. Zeitschrift
für Neuropsychologie;1:13–15.
9. Härting C, Markowitsch H, Neufeld H, Calabrese P, Deisinger K, Kessler J.
Wechsler Gedächtnis Test - Revidierte Fassung (WMS-R). Bern: Huber;
2000.
10. Delis DC, Freeland J, Kramer JH, Kaplan E. Integrating clinical assessment
with cognitive neuroscience: construct validation of the california verbal
learning test. J Consult Clin Psychol. 1988;56(1):123–30. 0022-006X (Print)
0022-006X (Linking) Journal Article.
11. Sturm W, Willmes K. Verbaler Lerntest (VLT). Göttingen: Hogrefe Verlag
für Psychologie.
12. Tewes R. Hamburg-Wechsler Intelligenztest Für Erwachsene - Revision.
Bern: Huber; 1991.
13. Osterrieth P. Le test de copie d’une figure complex: Contribution a l’étude
de la perception et de la memoire. Archives de Psychologie. 1944;30:
286–353.
14. Sturm W, Willmes K. Nonverbaler Lerntest (NVLT). Göttingen: Hogrefe
Verlag für Psychologie; 1999.
15. Bäumler G. Lern- und Gedächtnistest LGT-3. Göttingen: Hogrefe Verlag für
Psychologie; 1974.
16. Aschenbrenner S, Tucha O, Lange K. Regensburger Wortflüsigkeitstest.
Lisse: Swets und Zeitlinger Verlag; 2000.
17. Ruff R. Ruff Figural Fluency Test. Administration Manual. San Diego, CA,
USA: Neuropsychological Resources; 1988.
18. Nelson HE. A modified card sorting test sensitive to frontal lobe defects.
Cortex. 1976;12(4):313–24. 0010-9452 (Print) 0010-9452 (Linking) Journal
Article.
19. Simon HA. The functional equivalence of problem solving skills. Cognitive
Psychology;7:268–88.
20. Beck A, Ward C, Mendelson M, Mock J, Erbaugh J. An inventory for
measuring depression. Archives of General Psychiatry. 1961;4:561–71.
21. Hamilton M. Development of a rating scale for primary depressive illness.
Br J Soc Clin Psychol. 1967;6(4):278–96. 0007-1293 (Print) 0007-1293
(Linking) Journal Article.
22. Franke GH. Die Symptom-Checkliste Von Derogatis – Deutsche Version.
Göttingen: Beltz Test Gesellschaft.
23. Herrmann C, Buss U, Snaith RP. Hospital Anxiety and Depression Scale -
Deutsche Version (HADS-D). Manual. Bern, Göttingen: Huber; 1995.
24. Laux L, Glanzmann P, Schaffner P, Spielberger CD. Das
State-Trait-Angstinventar. Theoretische Grundlagen und
Handanweisung. Weinheim: Beltz Test; 1981.
Schmidt et al. BMC Neurology  (2015) 15:139 Page 11 of 11
25. Bennett R. The fibromyalgia impact questionnaire (fiq): a review of its
development, current version, operating characteristics and uses. Clin Exp
Rheumatol. 2005;23(5 Suppl 39):154–62. 0392-856X (Print) 0392-856X
(Linking) Journal Article.
26. Cella D, Lai JS, Chang CH, Peterman A, Slavin M. Fatigue in cancer
patients compared with fatigue in the general united states population.
Cancer. 2002;94(2):528–38. 0008-543X (Print) 0008-543X (Linking)
Comparative Study Journal Article Research Support, Non-U.S. Gov’t.
27. Diener E, Emmons RA, Larsen RJ, Griffin S. The satisfaction with life scale.
J Pers Assess. 1985;49(1):71–5. 0022-3891 (Print) 0022-3891 (Linking)
Journal Article.
28. Bullinger M. [assessment of health related quality of life with the sf-36
health survey]. Rehabilitation (Stuttg). 1996;35(3):. 0034-3536 (Print)
0034-3536 (Linking) Comparative Study English Abstract Journal Article.
29. Buysse DJ, Reynolds r. C. F., Monk TH, Berman SR, Kupfer DJ. The
pittsburgh sleep quality index: a new instrument for psychiatric practice
and research. Psychiatry Res. 1989;28(2):193–213. 0165-1781 (Print)
0165-1781 (Linking) Journal Article Research Support, U.S. Gov’t, P.H.S.
30. Smith SM, Rao A, De Stefano N, Jenkinson M, Schott JM, Matthews PM,
et al. Longitudinal and cross-sectional analysis of atrophy in alzheimer’s
disease: cross-validation of bsi, siena and sienax. Neuroimage. 2007;36(4):
1200–6. Smith, Stephen M Rao, Anil De Stefano, Nicola Jenkinson, Mark
Schott, Jonathan M Matthews, Paul M Fox, Nick C Neuroimage. 2007 Jul
15;36(4):1200-6. Epub 2007 Apr 27.
31. Group T. I. M. S. S. Interferon beta-1b is effective in relapsing-remitting
multiple sclerosis. i. clinical results of a multicenter, randomized,
double-blind, placebo-controlled trial. Neurology. 1993;43(4):655–1.
0028-3878 (Print) 0028-3878 (Linking) Clinical Trial Journal Article
Multicenter Study Randomized Controlled Trial.
32. Ravdin LD, Hilton E, Primeau M, Clements C, Barr WB. Memory
functioning in lyme borreliosis. J Clin Psychiatry. 1996;57(7):282–6.
0160-6689 (Print) 0160-6689 (Linking) Comparative Study Journal Article.
33. Skogman BH, Croner S, Nordwall M, Eknefelt M, Ernerudh J, Forsberg P.
Lyme neuroborreliosis in children: a prospective study of clinical features,
prognosis, and outcome. Pediatr Infect Dis J. 2008;27(12):1089–94.
0891-3668 (Print) 0891-3668 (Linking) Journal Article Randomized
Controlled Trial Research Support, Non-U.S. Gov’t.
34. Oksi J, Nikoskelainen J, Hiekkanen H, Lauhio A, Peltomaa M, Pitkaranta
A, et al. Duration of antibiotic treatment in disseminated lyme borreliosis:
a double-blind, randomized, placebo-controlled, multicenter clinical
study. Eur J Clin Microbiol Infect Dis. 2007;26(8):571–81. 0934-9723 (Print)
0934-9723 (Linking) Journal Article Multicenter Study Randomized
Controlled Trial Research Support, Non-U.S. Gov’t.
35. Ljostad U, Skogvoll E, Eikeland R, Midgard R, Skarpaas T, Berg A, et al.
Oral doxycycline versus intravenous ceftriaxone for european lyme
neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised
trial. Lancet Neurol. 2008;7(8):690–5. Ljostad, Unn Skogvoll, Eirik Eikeland,
Randi Midgard, Rune Skarpaas, Tone Berg, Ase Mygland, Ase England
Lancet Neurol. 2008 Aug;7(8):690-5. Epub 2008 Jun 21.
36. Borg R, Dotevall L, Hagberg L, Maraspin V, Lotric-Furlan S, Cimperman J,
et al. Intravenous ceftriaxone compared with oral doxycycline for the
treatment of lyme neuroborreliosis. Scand J Infect Dis. 2005;37(6-7):
449–54. 0036-5548 (Print) 0036-5548 (Linking) Clinical Trial Comparative
Study Journal Article Research Support, Non-U.S. Gov’t.
37. Eikeland R, Mygland A, Herlofson K, Ljostad U. European
neuroborreliosis: quality of life 30 months after treatment. Acta Neurol
Scand. 2011;124(5):349–54. Eikeland, R Mygland, A Herlofson, K Ljostad, U
Denmark Acta Neurol Scand. 2011 Nov;124(5):349-54.
doi:10.1111/j.1600-0404.2010.01482.x. Epub 2011 Feb 9.
38. Krupp LB, Masur D, Schwartz J, Coyle PK, Langenbach LJ, Fernquist SK,
et al. Cognitive functioning in late lyme borreliosis. Arch Neurol.
1991;48(11):1125–9. 0003-9942 (Print) 0003-9942 (Linking) Journal Article
Research Support, Non-U.S. Gov’t.
39. Djukic M, Schmidt-Samoa C, Nau R, von Steinbuchel N, Eiffert H,
Schmidt H. The diagnostic spectrum in patients with suspected chronic
lyme neuroborreliosis - the experience from one year of a university
hospital’s lyme neuroborreliosis outpatients clinic. Eur J Neurol. 2011;18(4):
547–5. 1468-1331 (Electronic) 1351-5101 (Linking) Journal Article.
40. Schmidt H, Heimann B, Djukic M, Mazurek C, Fels C, Wallesch CW, et al.
Neuropsychological sequelae of bacterial and viral meningitis. Brain.
2006;129(Pt 2):333–45. 1460-2156 (Electronic) 0006-8950 (Linking)
Comparative Study Journal Article Research Support, Non-U.S. Gov’t.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
